This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Accera And University Of Miami Announce Collaboration To Study Axona® For Cognitive Impairment In Patients With Multiple Sclerosis

BROOMFIELD, Colo., April 9, 2013 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today a study in collaboration with the University of Miami Miller School of Medicine. The study will examine the effects of Accera's medical food, Axona, on cognitive impairment in patients with multiple sclerosis (MS). Axona is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease (AD). Drs. Melissa Ortega and Heather Katzen, two researchers at the Miller School, will serve as the primary investigators of the study. The project will be funded by Fast Forward, LLC, a nonprofit organization established by the National Multiple Sclerosis Society.

More than 2.1 million people are affected by MS worldwide, and cognitive problems commonly occur in individuals with MS. Symptoms vary in severity and may have a negative impact on relationships, work and quality of life. There are few treatment options available and there is a pressing need for new interventions for cognitive impairment in MS. The UM Miller School of Medicine and Accera, with support from Fast Forward, LLC, will be testing Axona as a unique strategy for improving cognitive function in individuals with MS to address this disabling symptom.

Axona, made from special fats, produces ketones, which can provide an alternative energy source for brain cells.  While typically the human brain relies on glucose as an energy source, research shows that individuals with AD fail to metabolize glucose properly. The decrease in glucose use correlates with cognitive impairment associated with the disease. In clinical trials, Axona was associated with cognitive improvement in people with mild to moderate AD. Previous research suggests there may also be flaws in how glucose is metabolized in the brains of individuals with MS. The notion that these metabolic abnormalities may be contributing to cognitive dysfunction in MS is what led Dr. Ortega, a neurologist who specializes in MS, to consider whether Axona may provide a therapeutic strategy to treat MS-related cognitive problems. To investigate whether Axona can help restore cognitive function in MS patients, this double-blind, randomized, placebo-controlled study will enroll 158 MS patients at the UM Miller School of Medicine MS Center over the next three years who have experienced cognitive problems.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs